InspireMD Secures $58 Million in Funding Following FDA Approval of CGuard Prime Carotid Stent
InspireMD Inc. has successfully secured approximately $58 million in combined gross proceeds through equity private placement and warrant exercises following the FDA's premarket application approval of their CGuard Prime carotid stent system. This financial boost, detailed in their Form 8-K filing, will support the commercialization of the stent system, which is designed to prevent strokes. The PIPE, totaling $40.1 million, was led by investors OrbiMed and Marshall Wace, with contributions from both new and existing investors, as well as InspireMD board members. BofA Securities facilitated the transaction, which is expected to close by August 1, 2025. The funds will be used to enhance sales, marketing, research, and overall operations as InspireMD prepares to expand its market presence in the U.S.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InspireMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021675), on July 31, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。